GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Pacira BioSciences Inc (NAS:PCRX) » Definitions » Cyclically Adjusted Price-to-FCF

Pacira BioSciences (Pacira BioSciences) Cyclically Adjusted Price-to-FCF : 23.61 (As of Jun. 08, 2024)


View and export this data going back to 2011. Start your Free Trial

What is Pacira BioSciences Cyclically Adjusted Price-to-FCF?

As of today (2024-06-08), Pacira BioSciences's current share price is $28.57. Pacira BioSciences's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 was $1.21. Pacira BioSciences's Cyclically Adjusted Price-to-FCF for today is 23.61.

The historical rank and industry rank for Pacira BioSciences's Cyclically Adjusted Price-to-FCF or its related term are showing as below:

PCRX' s Cyclically Adjusted Price-to-FCF Range Over the Past 10 Years
Min: 21.69   Med: 61.26   Max: 742.18
Current: 23.56

During the past years, Pacira BioSciences's highest Cyclically Adjusted Price-to-FCF was 742.18. The lowest was 21.69. And the median was 61.26.

PCRX's Cyclically Adjusted Price-to-FCF is ranked better than
59.63% of 322 companies
in the Drug Manufacturers industry
Industry Median: 31.865 vs PCRX: 23.56

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

Pacira BioSciences's adjusted free cash flow per share data for the three months ended in Mar. 2024 was $0.886. Add all the adjusted free cash flow per share for the past 10 years together and divide 10 will get our Cyclically Adjusted FCF per Share, which is $1.21 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Pacira BioSciences Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Pacira BioSciences's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pacira BioSciences Cyclically Adjusted Price-to-FCF Chart

Pacira BioSciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - 66.68 31.51

Pacira BioSciences Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 59.80 48.49 31.64 31.51 24.10

Competitive Comparison of Pacira BioSciences's Cyclically Adjusted Price-to-FCF

For the Drug Manufacturers - Specialty & Generic subindustry, Pacira BioSciences's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pacira BioSciences's Cyclically Adjusted Price-to-FCF Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Pacira BioSciences's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Pacira BioSciences's Cyclically Adjusted Price-to-FCF falls into.



Pacira BioSciences Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Pacira BioSciences's Cyclically Adjusted Price-to-FCF for today is calculated as

Cyclically Adjusted Price-to-FCF=Share Price/ Cyclically Adjusted FCF per Share
=28.57/1.21
=23.61

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pacira BioSciences's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Pacira BioSciences's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2024 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0.886/131.7762*131.7762
=0.886

Current CPI (Mar. 2024) = 131.7762.

Pacira BioSciences Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201406 0.062 100.560 0.081
201409 0.112 100.428 0.147
201412 0.164 99.070 0.218
201503 -0.209 99.621 -0.276
201506 -0.112 100.684 -0.147
201509 -0.165 100.392 -0.217
201512 0.193 99.792 0.255
201603 -0.275 100.470 -0.361
201606 -0.036 101.688 -0.047
201609 0.208 101.861 0.269
201612 0.333 101.863 0.431
201703 -0.095 102.862 -0.122
201706 -0.037 103.349 -0.047
201709 -0.203 104.136 -0.257
201712 0.292 104.011 0.370
201803 -0.193 105.290 -0.242
201806 0.266 106.317 0.330
201809 0.297 106.507 0.367
201812 0.461 105.998 0.573
201903 0.036 107.251 0.044
201906 0.489 108.070 0.596
201909 0.402 108.329 0.489
201912 0.512 108.420 0.622
202003 -0.012 108.902 -0.015
202006 -0.581 108.767 -0.704
202009 0.723 109.815 0.868
202012 0.721 109.897 0.865
202103 -0.022 111.754 -0.026
202106 0.430 114.631 0.494
202109 1.038 115.734 1.182
202112 0.309 117.630 0.346
202203 0.498 121.301 0.541
202206 0.344 125.017 0.363
202209 0.818 125.227 0.861
202212 0.796 125.222 0.838
202303 0.273 127.348 0.282
202306 0.770 128.729 0.788
202309 0.788 129.860 0.800
202312 0.665 129.419 0.677
202403 0.886 131.776 0.886

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Pacira BioSciences  (NAS:PCRX) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Pacira BioSciences Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Pacira BioSciences's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Pacira BioSciences (Pacira BioSciences) Business Description

Traded in Other Exchanges
Address
5401 West Kennedy Boulevard, Suite 890, Tampa, FL, USA, 33609
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company has launched EXPAREL which utilizes DepoFoam, a product delivery technology that encapsulates drugs without altering their molecular structure, and releases them over a desired period of time.
Executives
Marcelo Bigal director C/O PACIRA BIOSCIENCES, INC., 5401 WEST KENNEDY BOULEVARD, SUITE 890, TAMPA FL 33609
Abraham Ceesay director C/O SCPHARMACEUTICALS, INC., 2400 DISTRICT AVENUE SUITE 310, BURLINGTON MA 01830
Alethia Young director C/O GRAPHITE BIO, INC., 201 HASKINS WAY, SUITE 210, SOUTH SAN FRANCISCO CA 94080
Michael J. Yang director C/O ACADIA PHARMACEUTICALS INC., 12830 EL CAMINO REAL, SUITE 400, SAN DIEGO CA 92130
Roy Winston officer: Chief Clinical Officer C/O PACIRA BIOSCIENCES, INC,, 5401 WEST KENNEDY BOULEVARD, SUITE 890, TAMPA FL 33609
Lauren Bullaro Riker officer: Executive Director, Accounting C/O PACIRA PHARMACEUTICALS, INC., 5 SYLVAN WAY, PARSIPPANY NJ 07054
Kristen Marie Williams officer: CAO and General Counsel C/O PACIRA PHARMACEUTICALS, INC., 5 SYLVAN WAY, SUITE 300, PARSIPPANY NJ 07054
Mark A. Kronenfeld director C/O PACIRA PHARMACEUTICALS, INC., 5 SYLVAN WAY, SUITE 100, PARSIPPANY NJ 07054
Daryl Gaugler officer: Chief Operating Officer C/O PACIRA BIOSCIENCES, INC., 5 SYLVAN WAY, SUITE 300, PARSIPPANY NJ 07054
Reinhart Charles A. Iii officer: Chief Financial Officer C/O PACIRA PHARMACEUTICALS, INC., 5 SYLVAN WAY, SUITE 300, PARSIPPANY NJ 07054
Ellis Ronald J. Jr. officer: Chief Strategy Officer C/O TELA BIO, INC., 1 GREAT VALLEY PARKWAY, SUITE 24, MALVERN PA 19355
Max Reinhardt officer: President C/O PACIRA BIOSCIENCES, INC., 5 SYLVAN WAY, SUITE 300, PARSIPPANY NJ 07054
David M Stack director, officer: President and CEO THE MEDICINES CO, 8 CAMPUS DRIVE, PARSIPPANY NJ 07054
Dennis Mcloughlin officer: Chief Commercial Officer C/O PACIRA PHARMACEUTICALS, INC., 5 SYLVAN WAY, SUITE 300, PARSIPPANY NJ 07054
Jonathan Slonin officer: Chief Clinical Officer C/O PACIRA BIOSCIENCES, INC., 5 SYLVAN WAY, SUITE 300, PARSIPPANY NJ 07054